Quote:

---

What are the implications should NASH 700 reveals that 50% of the patients had a 160ms drop in cT1. Only that it would equate to a 7 - 8 point drop in NAS score. Since worst cast of NASH = NAS of 8, then, in 50% of patients, Leronlimab would be capable of reducing the worst case of NASH to grade 1 NAS or healthy liver.

---

I do not see a doubling of the dose from 350mg to 700mg having double the effect in NASH. I would have to go back and check but I think we were getting around 75% receptor coverage at 350mg vs. 100% for 700mg.

But that wouldn't necessarily mean a 25% improvement between 350mg and 700mg. It is the extremity of the inflammation that causes NASH and a very mild inflammation would not necessarily lead to scar tissue. Previously off the top of my head I was expecting a 15% - 20% improvement between the two doses. That percent up and above the 350mg would be extremely good.